Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)'. The following are the other... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and T... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In C... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasophar... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 i... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Clinical and Economic Outcomes of Adding Semaglutide to Standard of Care in Adult Pa... Read More
Singapore, May 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Inte... Read More